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To the Editor: The most comprehensive meta-analysis
published to date has demonstrated that the risk of
developing prostate cancer may be reduced in men with
diabetes mellitus, but the mechanisms responsible for this
association remain poorly understood [1]. In their recent
Commentary, Frayling et al. summarise currently available
data suggesting that this inverse relationship could in part
be explained by genetic factors [2]. Of note, it has been
shown that the same variation in the HNF1B (also known
as TCF2) gene, which is associated with increased prostate
cancer risk, confers protection against type 2 diabetes
mellitus [3].
Androgens play a key role in the pathogenesis of
prostate cancer [4, 5]. The enzyme 5α-reductase is able to
convert testosterone to the more active androgen, dihydro-
testosterone [4, 5]. Inhibition with finasteride of the type II
isoform of 5α-reductase, which is most abundant in
prostate tissue [4], is effective in the treatment of benign
prostatic hypertrophy [6], and reduces the risk of prostate
cancer development [5].
Based on the importance of 5α-reductase inhibition for
prostate cancer prevention, we propose a biologically
plausible hypothesis that might explain a lower risk of
prostate cancer in men with diabetes mellitus. This
hypothesis is complementary to effects of genetic factors
involving both diseases, as discussed by Frayling et al. [2].
5α-Reduction of androgens (C19 steroids) to androsterone
is dependent on NADPH as a cofactor (reviewed in [7]).
Importantly, under hyperglycaemic circumstances cellular
NADPH is likely to be decreased in many tissues,
consequent to increased aldose reductase-mediated conver-
sion of glucose to sorbitol [8]. We have previously shown
that the urinary ratio of androsterone to etiocholanolone
(reflecting the proportion of 5α- to 5β-reduced C19
steroids) is lower in type 1 diabetes patients; this ratio is
inversely related to the HbA1c level [7]. It thus seems
plausible that chronic hyperglycaemia could result in a
lower relative 5α-reductase activity via lower cellular
NADPH. Hence, hyperglycaemia could contribute to
diminished dihydrotestosterone availability in prostate
tissue from men with diabetes mellitus.
Obviously, it will be necessary to directly test whether
hyperglycaemia decreases 5α-reductase activity in pros-
tate tissue. In view of the proposed hypothesis, it is also
relevant to take account of the degree of metabolic con-
trol when evaluating the association of diabetes mellitus
with prostate cancer in epidemiological studies, which
was not done in any of the studies included in the meta-
analysis [1].
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